Online Ketamine Treatment Available in: AZ, CA, CO, FL, GA, NY, OR, TX, and WA.
Online Ketamine Treatment Available in: AZ, CA, CO, FL, GA, NY, OR, TX, and WA.
Chronic pain and depression are so frequently intertwined that separating them can feel almost artificial. Roughly 50 percent of patients with chronic pain meet criteria for depression, and people with depression report pain symptoms at significantly higher rates than the general population. The two conditions share neural circuitry, inflammatory pathways, and neurotransmitter systems — which raises an important clinical question: could a treatment that acts on shared mechanisms address both simultaneously? Ketamine, with its unique pharmacological profile, may be one such treatment.
The antidepressant properties of ketamine were first demonstrated in a controlled setting by Berman RM and colleagues in a study published in Biological Psychiatry in 2000 (PMID: 10686270). In this small but influential double-blind, placebo-controlled crossover trial, seven patients with major depression received a single subanesthetic intravenous infusion of ketamine. Within hours, patients showed significant improvement in depressive symptoms compared to placebo, an effect that persisted for several days. This study laid the groundwork for all subsequent research on ketamine as a rapid-acting antidepressant.
In parallel, the pain medicine field has long recognized ketamine's analgesic properties. Ketamine blocks NMDA receptors, which play a central role in central sensitization — the process by which the nervous system amplifies pain signals in chronic pain conditions. A systematic review by Orhurhu V and colleagues examined the evidence for ketamine in chronic pain management and found that subanesthetic ketamine infusions produced meaningful pain reduction across multiple chronic pain conditions, including complex regional pain syndrome, fibromyalgia, and neuropathic pain.
The intersection of these two bodies of literature is where the clinical picture becomes especially compelling. The NMDA receptor system that ketamine modulates is implicated in both pain processing and mood regulation. Glutamate dysregulation, neuroinflammation, and impaired neuroplasticity are features of both chronic pain and depression. By acting on this shared substrate, ketamine may produce simultaneous improvements in both domains — not as a side effect, but as a direct consequence of its mechanism of action.
For physicians treating patients with comorbid chronic pain and depression, the therapeutic challenge is well known. Many conventional antidepressants (particularly duloxetine and certain tricyclics) have some analgesic properties, but their onset is slow and their efficacy for both conditions is often partial. Opioid medications may address pain but can worsen depression and carry substantial risks of dependence. The result is often a complex polypharmacy regimen that creates its own problems.
Ketamine offers a mechanistically different approach. Its NMDA receptor antagonism addresses central sensitization (reducing pain amplification) while simultaneously promoting synaptic plasticity and BDNF release (improving mood). For the subset of patients whose pain and depression are deeply interconnected — where pain worsens mood and low mood amplifies pain perception — this dual action may break a cycle that other treatments cannot.
It is important to note that ketamine use for both chronic pain and depression remains off-label. The evidence, while promising, comes from relatively small studies and heterogeneous patient populations. Clinical decision-making should be individualized, taking into account the specific pain diagnosis, prior treatment history, and potential contraindications.
If you live with both chronic pain and depression, you are not imagining the connection between them. These conditions share biological underpinnings, and treating one in isolation often fails to resolve the other. Ketamine therapy, under physician supervision, may offer a way to address both conditions through a single treatment approach.
Patients with comorbid pain and depression should be especially proactive in communicating the full picture to their healthcare providers. If you are considering ketamine therapy primarily for depression but also experience chronic pain — or vice versa — that information can help your physician optimize your treatment plan and monitor outcomes across both domains.
Chronic pain and depression share overlapping neural mechanisms involving the NMDA receptor system, and ketamine's action on these shared pathways may allow it to treat both conditions simultaneously. For patients who have struggled with the interplay between pain and mood, ketamine represents a mechanistically rational treatment option that warrants discussion with a qualified physician.
References: Berman RM, et al. "Antidepressant effects of ketamine in depressed patients." Biological Psychiatry. 2000;47(4):351-354. PMID: 10686270. | Orhurhu V, et al. "Ketamine infusions for chronic pain: a systematic review and meta-analysis of randomized controlled trials." Anesthesia & Analgesia. 2019;129(1):241-254.
If you're considering ketamine therapy, Isha Health offers physician-led at-home treatment via telemedicine in California, New York, Texas, Florida, Colorado, Arizona, Georgia, Oregon, and Washington. No in-person visit required.
